What act is responsible for developing office based narcotic maintenance programs using buprenorphine?

The Drug Addiction Treatment Act is the legislation that specifically establishes the framework for the development and regulation of office-based narcotic maintenance programs utilizing buprenorphine. This act allows qualified physicians to provide treatment for opioid addiction in an office setting, which expands access to treatment for individuals struggling with opioid dependence. Buprenorphine, a partial opioid agonist, can be prescribed by certified practitioners, and the act sets forth the necessary guidelines and regulations to ensure responsible use while mitigating risks associated with opioid prescriptions.

In contrast, while the Drug Enforcement Administration Act pertains to the regulatory authority of the DEA concerning controlled substances, and the Comprehensive Drug Abuse Prevention and Control Act lays the foundation for the scheduling of drugs and establishing a control system, neither of these directly address office-based maintenance programs. The Narcotic Control Act primarily deals with the restrictions and regulations surrounding narcotic drugs, but it does not contain specific provisions for the current treatment approaches available for addiction management, such as those involving buprenorphine under the Drug Addiction Treatment Act.